BioCentury
ARTICLE | Financial News

Imago to deploy $40M series B for Phase II trials

March 21, 2019 6:54 PM UTC

Imago raised $40 million Thursday in a tranched series B round led by new investor Omega Funds to support completing Phase II trials of its lead compound, IMG-7289, for hematological indications.

An Imago BioSciences Inc. (San Francisco, Calif.) spokesperson told BioCentury the funding is expected to provide at least 36 months of runway...